MRC1 and melanoma: This prospective diagnostic open-label, non-randomized, feasibility study aimed to visualize CD206 + cells including M2-like TAM in target lesions (T-Lesion) of melanoma patients treated with immunotherapy using [99mTc]Tc-Tilmanocept imaging.